• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $KDNY

    Chinook Therapeutics Inc.

    Subscribe to $KDNY
    $KDNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other primary glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase Ib trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. The company is headquartered in Seattle, Washington.

    IPO Year: 2015

    Exchange: NASDAQ

    Website: chinooktx.com

    Peers

    $AKBA
    $ARDX
    $ATXI
    $DMAC
    $RPTX
    $TVTX

    Recent Analyst Ratings for Chinook Therapeutics Inc.

    DatePrice TargetRatingAnalyst
    8/8/2023$42.00Outperform → Neutral
    Wedbush
    3/6/2023$41.00Overweight
    Piper Sandler
    3/1/2023$43.00Buy
    Guggenheim
    12/5/2022$30.00Overweight
    Wells Fargo
    6/28/2022$30.00Buy
    Stifel
    See more ratings